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Microalbuminuria and Peripheral Arterial Disease Are
Independent Predictors of Cardiovascular and All-Cause
Mortality, Especially Among Hypertensive Subjects
Five-year Follow-up of the Hoorn Study
Agnes Jager, Piet J. Kostense, Henricus G. Ruhé, Robert J. Heine, Giel Nijpels, Jacqueline M. Dekker,
Lex M. Bouter, Coen D.A. Stehouwer
Abstract—Microalbuminuria (MA) is associated with increased cardiovascular and all-cause mortality. It has been
proposed that MA reflects generalized atherosclerosis and may thus predict mortality. To investigate this hypothesis, we
studied the associations between, on the one hand, MA and peripheral arterial disease (PAD), a generally accepted
marker of generalized atherosclerosis, and, on the other hand, cardiovascular and all-cause mortality in an age-, sex-,
and glucose tolerance-stratified sample (n5631) of a population-based cohort aged 50 to 75 years followed
prospectively for 5 years. At baseline, the albumin-to-creatinine ratio (ACR) was measured in an overnight spot urine
sample; MA was defined as ACR.2.0 mg/mmol. PAD was defined as an ankle-brachial pressure index below 0.90
and/or a history of a peripheral arterial bypass or amputation. After 5 years of follow-up, 58 subjects had died (24 of
cardiovascular causes). Both MA and PAD were associated with a 4-fold increase in cardiovascular mortality. After
adjusting for age, sex, diabetes mellitus, hypertension, levels of total and HDL-cholesterol and triglyceride, body mass
index, smoking habits, and preexistent ischemic heart disease, the relative risks (RR) (95% confidence intervals) were
3.2 (1.3 to 8.1) for MA and 2.4 (0.9 to 6.1) for PAD. When both MA and PAD were included in the multivariate analysis,
the RRs were 2.9 (1.1 to 7.3) for MA and 2.0 (0.7 to 5.7) for PAD. MA and PAD were both associated with an about
2-fold increase in all-cause mortality. The RRs of all-cause mortality associated with MA and PAD were about 4 times
higher among hypertensive than among normotensive subjects. We conclude that both MA and PAD are associated with
an increased risk of cardiovascular mortality. MA and PAD are mutually independent risk indicators. The associations
of MA and PAD with all-cause mortality are somewhat weaker. They are more pronounced in the presence of
hypertension than in its absence. These data suggest that MA affects mortality risk through a mechanism different from
generalized atherosclerosis.(Arterioscler Thromb Vasc Biol. 1999;19:617-624.)
Key Words: microalbuminurian peripheral arterial diseasen mortality n noninsulin dependent diabetes mellitus
n hypertension
The estimation of individual cardiovascular risk over andabove the assessment of classic risk factors, such as age,
hypercholesterolemia, and hypertension, is an important pre-
requisite for focusing preventive measures. It has been
suggested that the presence of microalbuminuria (MA) and
peripheral arterial disease (PAD) can identify subjects at
especially high risk.1–8
It is thought that the excess risk associated with MA and
PAD cannot be attributed solely to an increased prevalence of
conventional risk factors, such as hypertension, smoking, and
noninsulin-dependent diabetes mellitus.4,8–13Current hypoth-
eses aiming to explain the association of MA and PAD with
incident cardiovascular disease have focused on the possibil-
ity that both MA and PAD may be markers of generalized
atherosclerosis.14–17The evidence for this is stronger for PAD
than for MA. An alternative hypothesis is that MA is a marker
of a generalized vascular, possibly endothelial, dysfunction
that is distinct from atherosclerosis.18
To investigate these issues, we examined, in a prospective
cohort study, the relations between MA and PAD on the one
hand and cardiovascular and all-cause mortality on the other.
We reasoned that, if MA affects risk of mortality through
generalized atherosclerosis, the association of MA with
mortality would be weakened by adjusting for the presence of
PAD, which, as a marker of generalized atherosclerosis,
would be an intermediate in the causal pathway linking MA
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with mortality. If, on the other hand, MA and PAD confer
mutually independent excess risks of mortality, this would
argue against the idea that MA affects risk through general-
ized atherosclerosis. In addition, such a finding would have
important consequences for individual risk assessment be-
cause both measurements would be useful for estimation of
cardiovascular risk.
Subjects and Methods
The study population consisted of an age-, sex-, and glucose
tolerance-stratified sample of the Hoorn study, a population-based
cohort study of disturbances of glucose tolerance in a white popu-
lation aged 50 to 75 years conducted from October 1989 until
February 1992, as described previously.19 In brief, 2484 white
subjects (71% of those invited) participated. All subjects, except
previously diagnosed diabetic subjects treated with oral glucose-
lowering agents or insulin, underwent an oral glucose tolerance test
(OGTT) according to the WHO guidelines.20 Subjects with a 2-hour
post-load glucose$7.5 mmol/L, all subjects with noninsulin-
dependent diabetes mellitus (NIDDM), and a random sample of
subjects with a 2-hour post-load glucose,7.5 mmol/L stratified by
age and sex were invited within 4 weeks for a second visit to
investigate glucose intolerance-related complications (709 invited, of
whom 631 (89%) participated). These subjects underwent a second
OGTT (except those who already used blood glucose-lowering
agents; n567). On the basis of the 2 OGTTs, glucose tolerance was
divided into 3 categories20: normal glucose tolerance (NGT; n5288),
impaired glucose tolerance (IGT; n5170), and NIDDM (n5173).
We chose this procedure for reasons of efficiency, because we
wished to study a smaller, but still random, sample in more detail.
Subjects with NGT, IGT, or NIDDM in the present study population
were thus a random sample of all subjects with NGT, IGT, or
NIDDM in the initial cohort. The prevalences of NGT, IGT, and
NIDDM, and of associated variables, such as microalbuminuria, in
the present study population are not the same as in the initial cohort,
but because the exact sampling procedure is known, we can
back-calculate the prevalences in the initial cohort (n52484) from
those in the second sample (n5631), as previously described in
detail.19,21
From these subjects, we obtained an ankle-brachial blood pressure
index (ABPI) (n5631), a resting ECG (ECG) (n5625), and an
early-morning, first-voided spot urine sample to measure the urinary
albumin-to-creatinine ratio (ACR) (n5607). Urinary albumin was
measured by rate nephelometry (Array Protein System, Beckman)
with a threshold of 6.2 mg/L and intra- and interassay coefficients of
variation of#5% and#8%, respectively.22 Urinary creatinine was
measured by a modified Jaffé method. Subjects were classified as
having PAD when they had an ABPI,0.9 and/or when they had
undergone a peripheral arterial bypass or amputation. (A reproduc-
ibility test of the Doppler-assisted systolic blood pressure measure-
ments to obtain the ABPI was performed in a random sample
(n541), within 6 to 9 months after the first measurement.) The
agreement between the 2 examinations for the criteria of ABPI
,0.90, expressed as kappa, was 0.73 [95% confidence interval (CI)
0.49 to 0.98] indicating good agreement. An ABPI.1.50 (a level
possibly indicating medial arterial calcification23) could not be
detected in any of the subjects. Subjects were classified as having
preexistent ischemic heart disease (IHD) when they had an ECG with
a Minnesota code 1.1 to 1.3, 4.1 to 4.3, 5.1 to 5.3, or 7.1 and/or had
undergone coronary bypass surgery or angioplasty; as having cere-
brovascular disease when they had evidence of a past transient
ischemic attack or stroke according to the WHO cardiovascular
questionnaire24; and as having microalbuminuria (MA) when they
had an urinary albumin concentration greater than the assay thresh-
old (6.2 mg/L; n5336)andan ACR.2.0 mg/mmol. (An overnight
ACR .2.0 mg/mmol has a high sensitivity to detect an albumin
excretion rate.30 mg/min25). Of all urine samples, 32 were
excluded because of the use of an angiotensin-converting enzyme
inhibitor. In a representative sample of 174 subjects, 2 urine
collections were available and the presence of MA for these subjects
was therefore based on the mean ACR of the 2 urine collections.
Blood pressure was calculated as the mean of 4 measurements,
performed on 2 different occasions, using a random-zero sphygmo-
manometer under standardized conditions. Hypertension was defined
as diastolic pressure$95 mm Hg, systolic pressure$160 mm Hg
and/or the use of antihypertensive drugs.26 Data on weight, height,
body mass index (BMI), smoking habits, glycated hemoglobin
(HbA1c), fasting specific plasma insulin, fasting serum creatinine,
total cholesterol, HDL-cholesterol, and triglyceride levels were
obtained.19,21 Low density lipoprotein-cholesterol was calculated by
the Friedewald formula,27 except when triglyceride level was
.4.55 mmol/L (n523). The creatinine clearance was calculated
from serum creatinine using the Cockcroft and Gault formula.28
Normal renal function and mild and moderate renal failure were
defined as creatinine clearance.80, 51 to 80, and,51 mL/min,
respectively. (There were no subjects with creatinine clearance,24
mL/min.) Smoking habits were obtained from a standardized ques-
tionnaire. Current smoking was defined as currently smoking ciga-
rettes and/or cigars.
Follow-up Measurements
Data on the subjects’ vital status on April 1, 1997 were collected
from the mortality register of the municipality of Hoorn. Of 49
subjects who moved out of town, information on vital status was
obtained from the new local municipalities. For each subject, we
determined whether or not death had occurred in the first 5 years of
follow-up. For all subjects who died, the cause of death was
extracted from the medical records of the general practitioner and the
hospital of Hoorn, verified by 2 physicians and classified according
to the ninth edition of theInternational Classification of Diseases.
Cardiovascular mortality was defined as codes 390 to 459, cancer
mortality as codes 140 to 240, and sudden death as code 798.
Information on cause of death could not be obtained for 6 (10%) of
the deceased subjects.
All participants gave informed consent for this study, which was
approved by the local ethics committee.
Statistical Analyses
All analyses were performed with theStatistical Package for the
Social Sciences(SPSS). Survival during 5 years of follow-up was
calculated by Kaplan-Meier curves for different groups and differ-
ences were tested by the logrank test. Predictors of 5-year cardio-
vascular and all-cause mortality were determined by Cox propor-
tional hazards multiple regression analysis, in all cases—because of
the stratification procedure—with adjustment for age, sex, IGT, and
NIDDM. Results are described as relative risks (RRs) (hazard ratios)
with 95% CIs.
Potential risk factors measured on a continuous scale were used as
such in the regression models, except for HDL-cholesterol and BMI,
because the association of these variables with all-cause mortality
was nonlinear. Therefore, a low HDL-cholesterol was defined as a
level ,0.9 mmol/L29 and obesity as BMI.27 kg/m2 for men and
.26 kg/m2 for women.30 Levels of fasting insulin and triglyceride
were log-transformed because of a better fit of the regression model.
To evaluate a possible effect-modifying role of potential risk factors,
Cox regression analyses were performed with the risk factor of
interest, MA (or PAD), and their product term in the model. A
significant relative risk for the product term was considered as effect
modification by that risk factor. To assess whether MA and PAD
were independently associated with mortality, regression analyses
were primarily adjusted for all risk factors that were statistically
significant in initial analyses and secondarily for other potential risk
factors of interest which showed no significant association in the
initial analyses.
To investigate whether MA and PAD affected risk of mortality
through similar pathways, regression analyses were performed that
included both MA and PAD as independent variables. Two-sided
probability values,0.05 were considered statistically significant.
Results
Table 1 shows characteristics of the study population. Of all
subjects with MA (n566), 23% had PAD, whereas among all
subjects with PAD (n569), 22% had MA. After 5 years of
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follow-up, 58 of the 631 subjects had died, of whom 24 (41%)
died of cardiovascular disease. Among NGT subjects, 22%
(2/9) of those with MA died and 18% (4/22) of those with
PAD; for IGT subjects, the rates were 7% (1/14) and 6%
(1/17), respectively; and for NIDDM subjects, 30% (10/33)
and 37% (11/30), respectively.
Cardiovascular Mortality
Age, hypertension, a low HDL-cholesterol level, triglyc-
eride level, NIDDM, and preexistent IHD were signifi-
cantly associated with cardiovascular mortality after ad-
justing for age, gender, IGT, and NIDDM (Table 2). In the
entire group, MA and PAD were both associated with
about 4-fold increased risk of cardiovascular death after
adjusting for age, gender, IGT, and NIDDM (Table 3;
Figure 1a and 1b). After further adjustment for hyperten-
sion, low level of HDL-cholesterol, triglyceride level, and
preexistent IHD, the RRs associated with MA and PAD
were 3.3 and 3.6, respectively (Table 3). After additional
adjustment for current smoking, obesity, and total choles-
terol level, the RR of MA was similar and the RR of PAD
decreased to 2.4 (Table 3; models 1 to 3).
Further analyses were aimed at investigating whether
cardiovascular mortality risks associated with MA and PAD
were independent of each other. Mutual adjustment of MA
and PAD did not materially change the RR for cardiovascular
mortality, even after adjusting for other risk factors (Table 3,
models 4 to 6). The risk of cardiovascular mortality showed
around 13-fold (2.9834.31; Table 3) increase if both MA and
PAD were present compared with absent (Figure 2).












Age, y 64 (7) 69 (6) 69 (7)
Gender, % male 48 55 54
Body mass index, kg/m2 27.1 (3.9) 28.5 (4.3) 28.3 (3.9)
Current smokers, % 27 39 39
Diastolic blood pressure, mm Hg 83 (10) 81 (12) 80 (12)
Systolic blood pressure, mm Hg 139 (19) 142 (23) 141 (24)
Hypertension, % 37 59 75
Antihypertensive drug treatment, % 26 52 71
Total cholesterol, mmol/L 6.6 (1.2) 6.6 (1.1) 6.8 (1.1)
LDL cholesterol, mmol/L 4.6 (1.1) 4.4 (0.8) 4.6 (0.9)
HDL cholesterol, mmol/L 1.29 (0.36) 1.18 (0.39) 1.1 (0.4)
Triglycerides, mmol/L 1.5 (0.8–3.0)* 2.1 (1.0–4.2)* 2.2 (1.1–4.4)*
NIDDM, % 24 57 67
Impaired glucose tolerance, % 28 19 8
HbA1c, % of hemoglobin 5.8 (1.2) 6.8 (2.0) 6.8 (1.3)
Fasting insulin, pmol/L 83 (48–162)* 98 (53–189)* 95 (45–183)*
Serum creatinine, mmol/L 91 (16) 104 (36) 117 (47)
Creatinine clearance, mL/min† 79 (18) 72 (21) 66 (24)
Mild renal failure, %‡ 52 52 58
Moderate renal failure, %§ 2 14 21
Preexistent IHD, %\ 13 32 42
Stroke, %¶ 5 2 0
Peripheral arterial disease, %# 9 28 42
Microalbuminuria, %** 10 26 48
Data are mean (standard deviation) unless otherwise indicated. LDL indicates low density
lipoprotein; HDL, high density lipoprotein; NIDDM, non-insulin-dependent diabetes mellitus; HbA1c,
glycated hemoglobin; IHD, ischemic heart disease.
*Median (10 to 90th percentiles).
†Calculated from serum creatinine using the Cockcroft and Gault formula.
‡Creatinine clearance, 51 to 80 mL/min.
§Creatinine clearance, 24 to 50 mL/min.
\Minnesota code, 1.1 to 1.3, 4.1 to 4.3, 5.1 to 5.3, or 7.1 on the ECG, coronary bypass operation,
or angioplasty.
¶Stroke or transient ischemic attack according to the WHO questionnaire.
#Ankle-brachial blood pressure index ,0.90 or peripheral arterial bypass operation or amputation.
**Albumin-to-creatinine ratio .2.0 mg/mmol.
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Age, obesity, current smoking, hypertension, levels of total
and HDL-cholesterol and triglyceride, NIDDM, and preexis-
tent IHD showed no significant interaction with MA or PAD
(all P.0.2, data not shown). Subgroup analyses in nondia-
betic and diabetic subjects separately showed higher RRs
associated with MA and PAD among diabetic compared with
nondiabetic subjects (Table 3). In a forward stepwise regres-
sion model, including all variables shown in Table 2, age,
current smoking, low level of HDL-cholesterol, NIDDM,
preexistent IHD, and MA were significantly associated with
cardiovascular mortality (Table 4).
Four subjects died of sudden death. When sudden death
was enclosed in the definition, the RRs of cardiovascular
mortality were 3.66 (1.59 to 8.39) for MA and 3.52 (1.52 to
7.72) for PAD in analyses similar to model 1 in Table 3.
Inclusion of serum creatinine or creatinine clearance (Ccr)
calculated from the Cockroft and Gault formula28 in the
analyses above slightly decreased the RRs for MA and PAD.
Further analyses showed that this was entirely due to subjects
with moderate renal failure (Ccr,51 mL/min; n522); after
exclusion of these subjects, the respective RRs were similar
to those in the initial analyses (data not shown).
All-Cause mortality
MA and PAD were both associated with an about 2-fold
increased risk of all-cause mortality after adjusting for age,
gender, IGT, and NIDDM (Table 5). Further adjustment for
current smoking, low level of HDL-cholesterol, level of
triglyceride, and preexistent IHD slightly decreased the RRs
associated with MA and PAD (to 1.85 and 1.64, respective-
ly). These RRs were similar after further adjustment for
obesity, hypertension, and total cholesterol level (Table 5).
Additional analyses indicated that the risk estimates for MA
and PAD were markedly (about 5- and 4-fold) higher in the
presence of hypertension than in its absence (P for interac-
tion50.15 and 0.08, respectively; Table 5). The RR of
mortality associated with MA among hypertensive nondia-
betic subjects (n5150) was 2.63 (0.64 to 10.83) in an analysis
analogous to model 1 in Table 5. Age, obesity, current
smoking, level of total and HDL-cholesterol and triglyceride,
NIDDM, and preexisting IHD showed no interaction with
MA or PAD with regard to risk of mortality (data not shown).
The RRs associated with MA and PAD, after adjusting for
age, gender, IGT, and NIDDM, were not importantly affected
by mutual adjustment; both remained about 2.0 (data not
shown). After further adjustment for current smoking, low
level of HDL-cholesterol, triglyceride level, and preexistent
IHD, the RRs (95% CIs) were 1.73 (0.89 to 3.38) for MA and
1.46 (0.73 to 2.91) for PAD. These RRs were similar after
further adjustment for obesity, hypertension, and total cho-
lesterol level (data not shown).
Inclusion of serum creatinine or creatinine clearance (Ccr)
calculated from the Cockroft and Gault formula28 in the
analyses above slightly decreased the RRs for MA and PAD.
Further analyses showed that this was entirely due to subjects
with moderate renal failure (Ccr,51 mL/min; n522); after
exclusion of these subjects, the respective RRs were similar
to those in the initial analyses (data not shown).
Twenty-six subjects (45%) died of cancer. Neither MA nor
PAD were significantly associated with cancer mortality
[RRs 0.96 (0.28 to 3.27) and 1.05 (0.36 to 3.07),
respectively].
Finally, we examined whether changing the definitions of
PAD and MA would affect our results. Lowering the ABPI
criterion from 0.9 to 0.8 or 0.7 did not materially affect the
results (data not shown). MA defined as ACR.3.0 mg/mmol
somewhat increased the RRs among diabetic subjects: for
example, the RR for all-cause mortality adjusted for age and
sex was 3.01 (1.34 to 6.75) versus 2.22 (1.01 to 4.87) when
MA was defined as ACR.2.0 mg/mmol. Other risk esti-
mates showed only minor changes (data not shown). Exclud-
ing subjects with macroalbuminuria (ACR.30 mg/mmol;
n56) gave similar results (data not shown). When MA was
defined on the basis of 1 overnight urine sample in all
subjects, the results were also similar (data not shown). Other
definitions of a low HDL-cholesterol and obesity also gave
similar results.
Discussion
This study shows that both MA and PAD are strongly
associated with 5-year risk of cardiovascular death. Mutual
adjustment did not markedly affect the relative risk estimates,
which argues against the idea that MA is a marker of
generalized atherosclerosis. Both MA and PAD are useful
measurements in estimating individual cardiovascular risk,
irrespective of the presence of IHD. In addition, our data
TABLE 2. Relative Risk of 5-year Cardiovascular and







Age, y 1.66 (1.15–2.39)† 1.63 (1.29–2.06)†
Gender, % male 1.62 (0.72–3.65) 1.73 (1.03–2.92)
Body mass index, kg/m2 1.61 (0.61–4.21)‡ 1.39 (0.76–2.51)‡
Current smokers, % 2.35 (0.99–5.54) 2.21 (1.28–3.82)
Hypertension, % 3.36 (1.29–8.76) 1.56 (0.91–2.69)
Total cholesterol, mmol/L 1.30 (0.95–1.79) 1.14 (0.92–1.40)
LDL cholesterol, mmol/L 1.31 (0.90–1.90) 1.09 (0.85–1.40)
HDL cholesterol, mmol/L 4.00 (1.66–9.65)§ 2.38 (1.28–4.43)§
Triglycerides, mmol/L 2.73 (1.28–5.80)\ 1.94 (1.17–3.21)\
NIDDM, % 4.19 (1.63–10.76) 3.72 (1.99–6.99)
Impaired glucose tolerance, % 0.50 (0.10–2.47) 1.21 (0.55–2.67)
HbA1c, % of hemoglobin 1.08 (0.84–1.38) 1.15 (0.98–1.34)
Fasting insulin, pmol/L 0.88 (0.35–2.26)\ 1.24 (0.68–2.24)\
Preexistent IHD, %¶ 3.14 (1.36–7.24) 2.05 (1.16–3.64)
Stroke, %# not applicable 0.35 (0.05–2.51)
LDL indicates low density lipoprotein; HDL, high density lipoprotein; HbA1c,
glycated hemoglobin; IHD, ischemic heart disease.
*Relative risk (95% CI) by Cox regression analyses of 5-year cardiovascular
and all-cause mortality of continuous or dichotomous variables after adjusting
for age, gender, impaired glucose tolerance, and NIDDM, except when this was
the variable under consideration.
†Per 5-year increase, with 50 to 55 years as reference.
‡.vs#27 kg/m2 for men and .vs#26 kg/m2 for women.
§,vs$0.9 mmol/L.
\Log-transformed.
¶Minnesota code, 1.1 to 1.3, 4.1 to 4.3, 5.1 to 5.3, or 7.1 on the ECG,
coronary bypass operation, or angioplasty.
#Stroke or transient ischemic attack according to the WHO questionnaire.
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suggest that MA and PAD are particularly strong risk
indicators among subjects with hypertension.
Our study confirms that MA and PAD are strong
indicators of an increased risk of cardiovascular mortality,
independent of the presence of important cardiovascular
risk factors such as hypercholesterolemia, smoking, and
hypertension.1– 8 PAD is thought to be a marker of gener-
alized atherosclerotic disease, which is a plausible expla-
nation for the increased risk of mortality in subjects with
PAD.14 –16 In contrast, it is unclear why MA is associated
with an increased mortality risk.1,2,4,6,8 It has been sug-
gested that MA, like PAD, is a marker of generalized
atherosclerosis.31–36 Two findings of the present study
argue against this idea. First, only about 25% of subjects
with MA also had PAD and vice versa. Second, the
increased risk of mortality conferred by the presence of
MA was not materially lowered by including PAD in the
multivariate regression model, which would have been
expected if MA affected risk through generalized
atherosclerosis.
How, then, can the association between MA and mor-
tality be explained? First, MA is associated with increased
levels of von Willebrand factor, thrombomodulin, fibrin-
ogen, thrombin–antithrombin III complexes and impaired
fibrinolytic activity and may thus be a marker of a
prothrombotic state.37–39 Second, MA may reflect a spe-
cific type of endothelial dysfunction18,40 distinct from
atherosclerosis per se. Finally, MA in part may be a marker
of a low-grade chronic inflammatory state,41 which itself is
associated with an increased risk of cardiovascular dis-
ease.42,43 Taken together, these data and the present study
support the hypothesis that MA and PAD affect risk
through different pathways. Further studies are needed to
address the mechanisms by which MA increases the risk of
cardiovascular disease in more detail.
We found that both MA and PAD were associated more
strongly with all-cause mortality among hypertensive than
among normotensive subjects (Table 5), although the
confidence intervals of the risk estimates clearly do not
exclude the possibility of significant associations of MA
and PAD with mortality among normotensive subjects. In
previous studies, the mortality risk associated with MA or
PAD has usually been adjusted for the presence of hyper-
tension1,2,4 or systolic or diastolic blood pressure.3,5,8
However, this does not necessarily rule out the presence of
an interaction with hypertension, as suggested by our
results. The explanation for these findings is not clear, but
it is noteworthy that, in the same population, we found the
presence of hypertension (and NIDDM) to be the strongest
determinants of MA.22 This, together with the present
results, raises the possibility that, in the presence of
hypertension, the pathogenetic backgrounds of MA and
PAD and of their link with mortality are distinct from
those in the absence of hypertension. These issues require
further investigation.

















1 Age, sex, IGT, NIDDM 1.85 (0.21–16.61) 5.70 (2.00–16.26) 4.58 (1.91–11.00) 2.24 (0.42–11.79) 4.35 (1.57–12.03) 3.75 (1.62–8.68)




2.99 (0.23–40.00) 5.60 (1.81–17.31) 3.33 (1.37–8.09) 2.80 (0.48–16.34) 4.21 (1.41–12.59) 3.58 (1.50–8.58)
3 Model 2 and obesity,¶
current smoking and
cholesterol level
1.38 (0.06–34.46) 5.68 (1.74–18.52) 3.22 (1.28–8.06) 3.13 (0.48–20.35) 2.56 (0.74–8.83) 2.36 (0.92–6.09)
4 Model 1 and MA or PAD# 1.84 (0.20–16.52) 5.50 (1.91–15.84) 4.31 (1.79–10.36) 1.58 (0.17–14.85) 3.34 (1.17–9.56) 2.98 (1.20–7.40)
5 Model 2 and MA or PAD# 2.30 (0.15–34.56) 5.23 (1.66–16.48) 2.87 (1.15–7.16) 2.84 (0.21–37.81) 3.17 (0.95–10.62) 2.74 (1.02–7.39)
6 Model 3 and MA or PAD# 0.99 (0.04–26.57) 5.20 (1.57–12.03) 2.86 (1.11–7.34) 5.93 (0.37–96.19) 1.85 (0.48–7.06) 1.99 (0.69–5.74)
*Relative risk (95% confidence interval) of 5-year cardiovascular mortality analyzed by Cox multiple regression analyses. Model 1, stratification variables; model
2, as model 1, plus all risk factors significantly associated with cardiovascular mortality (shown in Table 2, left column); model 3, as model 2, plus major risk factors
that were nonsignificant (Table 2).
†And/or peripheral arterial bypass or amputation.
‡HDL-cholesterol level, ,0.9 mmol/L.
§Log-transformed triglyceride levels.
\Minnesota code 1.1 to 1.3, 4.1 to 4.3, 5.1 to 5.3, or 7.1 on ECG, coronary bypass operation, or angioplasty.
¶Body mass index .vs#27.0 kg/m2 for men and .vs#26.0 kg/m2 for women.
#With the variable added which was not in the model already.
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MA was thus significantly associated with all-cause
mortality among hypertensive subjects, which is in agree-
ment with some,44,45but not all34 previous studies, whereas
other studies2,4,6,8 did not specifically examine this issue.
This result, however, has to be interpreted with caution,
because our study was not specifically designed to answer
this question and lacked information about duration and
type of hypertension. Nevertheless, our data add to accu-
mulating evidence that, among hypertensive subjects, both
overt proteinuria46,47and MA44,45may be markers of a poor
prognosis.
The clinical implication of our findings is that both
measurement of the ankle-brachial blood pressure index
and of the urinary albumin excretion is useful to estimate
individual risk (Tables 3 to 5). Both measurements are
easy to obtain. All-cause and cardiovascular mortality risk
are increased about 3-fold and 15-fold, respectively, when
both PAD and MA are present, compared with when both
are absent (Figure 2). It is especially noteworthy that the
association of MA with cardiovascular mortality is of the
same order of magnitude as those of NIDDM and preex-
istent ischemic heart disease (Table 4).
Our study had several limitations. In the majority of
subjects, MA was estimated from 1 urine sample, which
may have increased nondifferential misclassification, lead-
ing to an underestimation of the association with mortality.
The study was too small to establish definitively whether
MA and PAD are significantly stronger risk markers in
hypertensive than in normotensive subjects. The study was
also too small to investigate whether the increased mortal-
ity risk associated with MA among hypertensive subjects
varied with the mode of treatment of hypertension or its
duration, or with the level of blood pressure. Although we
found evidence against the concept that MA is a marker of
generalized atherosclerosis, we did not address alternative
mechanisms linking MA to mortality. Finally, our study
lacked the power to exclude with confidence the presence
of interaction between glucose tolerance status and MA (or
PAD) with respect to cardiovascular mortality. Both MA
and PAD were in fact more strongly associated with
cardiovascular mortality in diabetic than in nondiabetic
subjects, although this was not significant (Table 3).
However, it appears unlikely that such an interaction, if
present, would affect our main conclusion, ie, that MA and
PAD are mutually independent risk indicators.
In conclusion, we have shown that both MA and PAD
are independently associated with cardiovascular mortality
and so may affect risk through different pathways. Mea-
surement of the urinary albumin excretion and the ankle-
brachial pressure index are therefore useful to estimate
individual risk (Figure 2 and Table 4). Such information is
clinically useful, because it can help to individualize
decisions on, for example, cholesterol- and blood pressure-
lowering treatment. Furthermore, the associations of MA
and PAD with mortality seem more pronounced in hyper-
Figure 1. (a) Cardiovascular survival (Kaplan-Meier) according
to the absence versus the presence of microalbuminuria. (b)
Cardiovascular survival (Kaplan-Meier) according to the absence
versus the presence of peripheral arterial disease.
Figure 2. Relative risks of all-cause and cardiovascular mortal-
ity associated with microalbuminuria (MA) and/or peripheral ar-
terial disease (PAD), after adjusting for age, gender, impaired
glucose tolerance, and non-insulin-dependent diabetes mellitus
(stratification variables, see Methods).
TABLE 4. Relative Risk of 5-Year Cardiovascular Mortality:




Age, per 5-year increase 1.12 (1.03–1.21)
Current smoking 2.76 (1.07–7.10)
HDL-cholesterol, ,0.9 mmol/L 4.48 (1.78–11.25)
NIDDM 3.67 (1.36–9.95)
Preexistent IHD† 3.64 (1.46–9.05)
MA‡ 3.27 (1.31–8.17)
*Relative risk (95% confidence interval) analyzed by forward Cox regression
analyses with all potential risk factors (Table 2) in the model.
†Minnesota code 1.1 to 1.3, 4.1 to 4.3, 5.1 to 5.3, or 7.1 on the ECG,
coronary bypass operation, or angioplasty.
‡Albumin-to-creatinine ratio .2.0 mg/mmol.
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tensive than in normotensive subjects. Further studies are
needed to clarify the underlying pathophysiologic mecha-
nism linking MA to (cardiovascular) mortality, as this may
have additional therapeutic implications.
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